VANCOUVER, British Columbia, March 12, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has successfully performed all of the due diligence set out in the binding agreement to acquire the Biosynthesis Pharma Group (BSPG). With this process now complete, the Company anticipates the closing of the acquisition to occur within the next couple of weeks.
Through BSPG’s proprietary industrial scale extraction methodologies, the company produces a high-purity, bioactive CBD isolate at a purity level of 99.5%+ for use in pharmaceutical applications globally to benefit humans and animals suffering from a range of both critical and non-life-threatening illnesses. BSPG currently has the capability of processing over 1.5 metric tons of hemp biomass daily to extract CBD, terpenes and other cannabinoids, specifically CBG.
“Isodiol management and legal teams have done a tremendous job vetting and validating all operating and financial information of the BSPG companies”, stated Marcos Agramont, CEO of Isodiol International Inc. “With this acquisition closing imminently, we will control manufacturing of the world’s purest, most bioactive CBD isolate, and will control a true pharmaceutical grade CBD product that is backed by clinical data from world renowned institutions. The BSPG team has done an incredible job establishing its global operations and with this merger, we are now positioned to change the conversation around the world on CBD and other cannabinoids.”
As the acquisition closes, the Company will begin publishing the various findings from clinicals completed using the BSPG CBD isolate. Publishing this data will coincide with implementing commercialization strategies for the various markets this clinical data can be represented. Teams are currently being assembled in these countries with practitioner education seminars and establishing logistics being the focus.
“The education process needs to start at the government regulator and practitioner levels and Isodiol is committed to this process through various initiatives”, stated Marcos Agramont. “Through our partnership with Livecare we are assembling a team of world-class doctors, researchers and industry professionals in collaborating on research which will be shared through the Livecare interface for the public to access.”
There have been no changes to the acquisition price stated in the news release from December 17th, 2017.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.